Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Pieris Pharmaceuticals Inc (PIRS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Pieris Pharmaceuticals Inc's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
11.060 -0.020    -0.18%
06/05 - Closed. Currency in USD ( Disclaimer )
After Hours
10.720
-0.340
-3.074%
19:59:25 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 17,039
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 10.797 - 11.410
Pieris Pharmaceuticals Inc 11.060 -0.020 -0.18%

Pieris Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Pieris Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

48

Equity Type

ORD

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

Contact Information

Address 225 Franklin Street 26th Floor
Boston, 02110
United States
Phone 857 246 8998
Fax -

Top Executives

Name Age Since Title
Stephen S. Yoder 47 2010 CEO, President & Director
Bruce Levy - - Member of Clinical & Scientific Advisory Board
Michael S. Richman 62 2014 Independent Director
Peter Barnes - - Member of Clinical & Scientific Advisory Board
Padmanee Sharma - - Member of Clinical & Scientific Advisory Board
Vijay Kumar Kuchroo 68 - Member of Clinical & Scientific Advisory Board
Christopher P. Kiritsy 58 2016 Independent Director
Peter A. Kiener 71 2018 Independent Director
Ian Adcock - - Member of Clinical & Scientific Advisory Board
Gary Anderson - - Member of Clinical & Scientific Advisory Board
Dario A. Vignali - - Member of Clinical & Scientific Advisory Board
Matthew L. Sherman 67 2018 Independent Director
Oliver Eickelberg - - Member of Clinical & Scientific Advisory Board
James Arthur Geraghty 68 2017 Independent Chairman
Maya R. Said 46 2019 Independent Director
David Schwartz - - Member of Clinical & Scientific Advisory Board
E. John Werry - - Member of Clinical & Scientific Advisory Board
Michael A. Curran - - Member of Clinical & Scientific Advisory Board
Ann Barbier 59 2018 Independent Director
Fan Chung - - Member of Clinical & Scientific Advisory Board
Sally Wenzel - - Member of Clinical & Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PIRS Comments

Write your thoughts about Pieris Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Hasan BOZAN
Hasan BOZAN Jul 06, 2023 5:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
İt will be 5 dolars in 2 year
Magazzinografici Tre
Magazzinografici Tre Dec 02, 2021 8:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Low at 3.15Last close at 3.26today i will buy 3.95 close of the year?
Magazzinografici Tre
Magazzinografici Tre Nov 30, 2021 8:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
pre market at 3.45. Yesterday close a 3.32
Dusty Diffey
Dusty Diffey Aug 09, 2021 8:39AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is this stock worth buying at all?
Magazzinografici Tre
Magazzinografici Tre Aug 04, 2021 9:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Earning today
Adam Sifre
Adam Sifre Jun 30, 2021 7:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How is this stock in such a slump??
Gp Ad
Gp Ad May 27, 2021 4:16AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Today open 5$
Jobir Avezov
Jobir Avezov May 26, 2021 3:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
3.37$ isn't good to buy?
Zoltán Révész
Zoltán Révész May 26, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
SHORTING Time! Easy money :)
Julien Monnerie
Julien Monnerie May 26, 2021 6:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yeah i hesitate, what's your sell and buy objectif ?
Kurt Love
Kurt Love May 25, 2021 4:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email